Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 1999

View Archived Issues

Company Profile: Epic Therapeutics

Abciximab improves microvascular perfusion after stenting in acute myocardial infarction

Sepracor: year-end 1998 highlights

OSI Pharmaceuticals: Annual Report 1998

Immunomedics and NCI to study new class of anticancer agents

NeoPharm and Pharmacia & Upjohn reach licensing agreement for liposomal cancer formulations

DiagnoCure plans preclinical trials of its patented vectors in melanoma

Dura and Spiros update joint development programs

New oxazolidinones active against Gram-positive aerobic, anaerobic and other bacteria

Spotlight on double and triple enzyme inhibitors for treating cardiovascular disease

Orally active antifungal agents designed by Janssen scientists

Synthelabo patents potent and selective nAChR ligands

Purinoceptor antagonists claimed by Astra, useful for inflammatory diseases

Danish and Indian investigators disclose optically active nonsteroidal antiestrogens

U.S. patent extends coverage for Immune Response's TCR vaccine technology

Four U.S. patents provide additional protection for Corvas's rNAP program

Orphan Medical launches improved form of busulfan in U.S.

Anesta enters agreement with Novartis for transmucosal drug delivery

Combination pharmaco- and psychotherapy reduces recurrence of depression in elderly

Israeli authorities approve new indication for WinRho SDF

Soluble peptide complex AG-284 is well tolerated in MS patients

Schein to introduce new product for management of hemodialysis patients with anemia

Protein Sciences, Texas A&M combine intellectual property positions on BEVS

Multiple methods of nicotine replacement increase abstinence rates in smokers

Phase III enrollment for Colloral completed

Apollo and AHP to develop estrogen products for Alzheimer's therapy

NCI to conduct phase III trial of pure shark cartilage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.